

Please replace the paragraph beginning at page 2, line 19, with the following rewritten paragraph:

a2

--The chemotherapeutic drug is preferably selected from cis-platin, a chemotherapeutic anthraquinone, and a topoisomerase I inhibitor, such as camptothecin or a camptothecin analog. More preferably, the drug is adriamycin (doxorubicin), in which case the liposome-encapsulated form of the drug is preferably DOXIL®, a polyethylene glycol-coated liposomal doxorubicin.--

Please replace the paragraph beginning at page 3, line 19, with the following rewritten paragraph:

a3

--Figure 2 shows the survival rate of BALB/c mice injected intravenously with 5×10^5 M109 tumor cells and subsequently treated with DOXIL® (at day 7), alone or in combination with intravenous IL-2 in STEALTH® PEGylated SUV liposomes (at days 11, 14, and 17), or with liposomal IL-2 alone (at days 11, 14, and 17).--

Please replace the paragraph beginning at page 4, line 22, with the following rewritten paragraph:

a4

--The vesicle-forming lipids, preferably those making up SUV's, may contain about 1-10 mole percent of a lipid having a polar head group, typically a phosphate containing head group, derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and

24 10,000 daltons. The rate of clearance of liposomes from circulation is typically reduced by employing such PEG-derivatized, or "PEGylated", lipids. PEG coating is believed to inhibit nonspecific adsorption of serum proteins, thereby preventing nonspecific recognition of liposomes by macrophages (Papahadjopoulos, et al., 1991). Another advantage of these long-circulating liposomes is their good extravasation capacity and high accumulation in tumors (Lasic and Martin, 1995; Gabizon, et al., 1997). They are also referred to as sterically stabilized liposomes, SSL, or STEALTH® liposomes.--

Please replace the paragraph beginning at page 7, line 18, with the following rewritten paragraph:

25 --The chemotherapeutic drug is preferably encapsulated in liposomes having about 1-10 mole percent of a PEGylated lipid, as described above. For example, DOXIL®, a stable formulation of adriamycin in STEALTH® liposomes, is available from SEQUUS Pharmaceuticals, Inc. (Menlo Park, CA). Free adriamycin is available, e.g., from Cetus Oncology Corp. (Emeryville, CA) as a formulation of doxorubicin hydrochloride and lactose.--

IN THE CLAIMS

Please cancel claims 1-30.

Please insert new claims 31-53 as follows: